IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive: This mechanism may be relevant in CML, since it was shown that cells of IFNa-resistant patients lack STAT1 expression [17] and in PV, when STAT1 function is inhibited by ruxolitinib.